DE69834556T2 - Modifizierte humane TNFalpha-Moleküle, DNA, welche für derartige veränderte TNFalpha-Moleküle kodieren und Impfstoffe, die derartige veränderte TNFalpha-Moleküle und DNA enthalten - Google Patents

Modifizierte humane TNFalpha-Moleküle, DNA, welche für derartige veränderte TNFalpha-Moleküle kodieren und Impfstoffe, die derartige veränderte TNFalpha-Moleküle und DNA enthalten Download PDF

Info

Publication number
DE69834556T2
DE69834556T2 DE69834556T DE69834556T DE69834556T2 DE 69834556 T2 DE69834556 T2 DE 69834556T2 DE 69834556 T DE69834556 T DE 69834556T DE 69834556 T DE69834556 T DE 69834556T DE 69834556 T2 DE69834556 T2 DE 69834556T2
Authority
DE
Germany
Prior art keywords
tnfα
molecule
modified
sheet
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834556T
Other languages
German (de)
English (en)
Other versions
DE69834556D1 (de
Inventor
Roland Martin JENSEN
Soren Mouritsen
Henrik Elsner
Iben Dalum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
Affitech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affitech AS filed Critical Affitech AS
Publication of DE69834556D1 publication Critical patent/DE69834556D1/de
Application granted granted Critical
Publication of DE69834556T2 publication Critical patent/DE69834556T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69834556T 1997-04-15 1998-04-15 Modifizierte humane TNFalpha-Moleküle, DNA, welche für derartige veränderte TNFalpha-Moleküle kodieren und Impfstoffe, die derartige veränderte TNFalpha-Moleküle und DNA enthalten Expired - Fee Related DE69834556T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
US44187P 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (2)

Publication Number Publication Date
DE69834556D1 DE69834556D1 (de) 2006-06-22
DE69834556T2 true DE69834556T2 (de) 2007-05-10

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834556T Expired - Fee Related DE69834556T2 (de) 1997-04-15 1998-04-15 Modifizierte humane TNFalpha-Moleküle, DNA, welche für derartige veränderte TNFalpha-Moleküle kodieren und Impfstoffe, die derartige veränderte TNFalpha-Moleküle und DNA enthalten

Country Status (29)

Country Link
US (1) US7118750B1 (enExample)
EP (1) EP0975668B1 (enExample)
JP (1) JP2001521386A (enExample)
KR (1) KR100522289B1 (enExample)
CN (1) CN1178955C (enExample)
AR (1) AR012427A1 (enExample)
AT (1) ATE326481T1 (enExample)
AU (1) AU743400B2 (enExample)
BR (1) BR9811462A (enExample)
CA (1) CA2289476A1 (enExample)
CZ (1) CZ9903657A3 (enExample)
DE (1) DE69834556T2 (enExample)
DK (1) DK0975668T3 (enExample)
EE (1) EE9900461A (enExample)
ES (1) ES2264569T3 (enExample)
HR (1) HRP980203B1 (enExample)
HU (1) HUP0001930A3 (enExample)
IL (1) IL132281A0 (enExample)
NO (1) NO995002L (enExample)
NZ (1) NZ337955A (enExample)
PL (1) PL194221B1 (enExample)
RU (1) RU2241715C2 (enExample)
SI (1) SI0975668T1 (enExample)
SK (1) SK285639B6 (enExample)
TR (1) TR199902562T2 (enExample)
TW (1) TW510921B (enExample)
UA (1) UA72440C2 (enExample)
WO (1) WO1998046642A1 (enExample)
ZA (1) ZA983148B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
AU2001265830A1 (en) * 2000-06-21 2002-01-02 Ferring, B.V. Solubilised protein vaccines
AU2003208314A1 (en) * 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2005084198A2 (en) 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2648746A1 (en) 2010-12-08 2013-10-16 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
WO2016179430A1 (en) 2015-05-05 2016-11-10 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
HK1022918A1 (en) 2000-08-25
ATE326481T1 (de) 2006-06-15
EP0975668B1 (en) 2006-05-17
TR199902562T2 (xx) 2000-02-21
DE69834556D1 (de) 2006-06-22
PL194221B1 (pl) 2007-05-31
CN1252809A (zh) 2000-05-10
BR9811462A (pt) 2000-09-12
NO995002L (no) 1999-12-15
KR20010006416A (ko) 2001-01-26
IL132281A0 (en) 2001-03-19
NZ337955A (en) 2000-09-29
HUP0001930A2 (hu) 2000-09-28
NO995002D0 (no) 1999-10-14
ES2264569T3 (es) 2007-01-01
EP0975668A1 (en) 2000-02-02
RU2241715C2 (ru) 2004-12-10
CN1178955C (zh) 2004-12-08
PL336295A1 (en) 2000-06-19
SK140999A3 (en) 2000-06-12
JP2001521386A (ja) 2001-11-06
AR012427A1 (es) 2000-10-18
HRP980203B1 (en) 2003-04-30
US7118750B1 (en) 2006-10-10
KR100522289B1 (ko) 2005-10-19
HUP0001930A3 (en) 2001-10-29
AU7030398A (en) 1998-11-11
WO1998046642A1 (en) 1998-10-22
UA72440C2 (en) 2005-03-15
TW510921B (en) 2002-11-21
HRP980203A2 (en) 1998-12-31
SK285639B6 (sk) 2007-05-03
AU743400B2 (en) 2002-01-24
CA2289476A1 (en) 1998-10-22
CZ9903657A3 (cs) 2001-09-12
EE9900461A (et) 2000-06-15
DK0975668T3 (da) 2006-09-25
ZA983148B (en) 1999-10-15
SI0975668T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
DE69924392T2 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
EP0975668B1 (en) MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA
DE69507507T2 (de) Konjugate bdnf und nt-3 mit einem wasserlöslichen polymer
DE60036552T2 (de) Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen
DE60213615T2 (de) Beta-amyloid-analog - t-zell epitop impfstoff
DE69408342T2 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
DE3751553T2 (de) Immunomodulare mittel und deren verwendung.
DE60114157T2 (de) Verfahren zur herabregulierung von amyloid
DE69738329T2 (de) Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins
DE69332485T2 (de) Immunmodulierende peptide
DE69927262T2 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
DE69333110T2 (de) Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
DE69534374T2 (de) Methoden und zubehör zur immunisierung von wirtsorganismen durch verabreichung nackter polynucleotide , welche für antigene peptide codieren
DE69837606T2 (de) Cystein-reiche rezeptoren-train
US7070784B1 (en) Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues
AT410635B (de) Vakzin-zusammensetzung
DE69934970T2 (de) Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten
DE3856059T2 (de) Peptid-Determinante mit Einfluss auf die Immunität
DE69033937T2 (de) Verfahren zur Herstellung von genetischen Vektoren zur Expression vom Nerven-Wachstumsfaktor in eukaryotischen Zellen
DE69133484T2 (de) Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
DE60301944T2 (de) Verfahren zur Vorbereitung von hypoallergenen Mosaikproteinen#
DE69937570T2 (de) Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
DE60205907T2 (de) Hypoallergene Impfstoffe gegen Allergie basierend auf Lieschgraspollenallergen Phl p 7
DE69230106T2 (de) Peptid-antigene bestehend aus multi-determinanten, die die t-helfer lymphozyten-antwort gegen hiv in einem weiten bereich von betroffenen menschen stimulieren
EP1425303A2 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee